What are the limitations of the r ipi revised ipi?

While the r ipi revised ipi is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the r ipi revised ipi to ensure safe bedside use and optimal diagnostic accuracy.

How does the r ipi revised ipi compare to other Hematology scores?

The r ipi revised ipi is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the r ipi revised ipi free to use?

Yes. OpiCalc provides the r ipi revised ipi completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

R-IPI (Revised IPI)

Revised IPI (R-IPI): Recalibrated for patients receiving Rituximab (R-CHOP). Identifies a "Very Good" group with exceptional survival.

R-IPI Prediction

Very Good

Estimated 4-y OS

94%

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Prognostication of DLBCL in patients receiving modern immunochemotherapy (e.g., R-CHOP).

To identify patients with extremely favorable outcomes (the "Very Good" group).

Better defining risk in the rituximab era compared to the original IPI.

Patient Population

Adult patients with newly diagnosed DLBCL treated with R-CHOP or similar rituximab-containing regimens.

When Not to Rely on This Score Alone

Double-hit or Triple-hit lymphomas — these biologically high-risk diseases may have poor outcomes regardless of R-IPI.

Limited-stage disease (Stage I) — localized therapy considerations often take precedence.

Section 2

Formula & Logic

Variables (Same as IPI)

Age > 60

LDH > ULN

ECOG ≥ 2

Stage III/IV

Extranodal Sites > 1

Recalibrated Risk Groups

Score	Risk Group	Estimated 4-y OS
0	Very Good	94%
1 - 2	Good	79%
3 - 5	Poor	55%

Section 3

Pearls/Pitfalls

The "Very Good" Group

The primary advantage of R-IPI is the identification of a R-CHOP-cured population (Score 0) with a 4-year OS of nearly 95%, which was not distinguishable using the original IPI.

Section 4

Evidence Appraisal

Primary Score

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH et al. • Blood. 2007;109(5):1857-61.

View Source

Section 5

Literature

Update

Developed by the British Columbia Cancer Agency (BCCA) group. They demonstrated that while the same 5 risk factors were still valid in the rituximab era, the prognosis of each group had significantly improved, requiring new grouping.

Last Comprehensive Review: 2026

Related Hematology Tools

ELN 2022 AML Risk Classification

JAK2V617F Allele Burden Interpreter

Sokal/EUTOS/ELTS Comparison

IPI

Have feedback about this calculator?Let us know.